title: [Effect of Chuanhuang No. 1 recipe on renal function and micro-inflammation in phase 3 chronic kidney disease patients].
abstract: OBJECTIVE
  To observe the effect of Chuanhuang No.1 Recipe (CHR) on renal function and micro-inflammation in phase 3 chronic kidney disease (CKD) patients.
  
  
  METHODS
  Totally 60 phase 3 CKD patients were randomly assigned to the treatment group (treated by CHR) and the control group (treated by Losartan Potassium), 30 in each group. All patients received basic treatment. Patients in the treatment group took CHR decoction, 400 mL each time, one dose per day, while those in the control group took Losartan Potassium, 50-100 mg per day. All medication lasted for 24 weeks. Changes of serum creatinine (SCr), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), serum uric acid (UA), 24 h urinary protein excretion (24 h U-pro), urinary microalbumin (U-Alb), high-sensitivity C-reactive protein (hs-CRP), serum tumor necrosis factor (TNF)-alpha, and serum IL-6 were detected and compared before and after treatment. Efficacy was also compared.
  
  
  RESULTS
  Compared with before treatment, SCr and BUN significantly decreased in the treatment group (P<0.05, P<0.01); eGFR in- creased (P<0.05). Only UA obviously decreased in the control group (P<0.05), but with no obvious change in SCr, BUN, or eGFR. Compared with before treatment, 24 h U-pro decreased after treatment in the treatment group (P<0.05), but with less decreased level when compared with the control group. U- Alb was also significantly decreased in the control group (P<0.01). There was statistical difference in 24 h U-pro and U-Alb between the two groups after treatment (P<0.05). Compared with before treatment, hs-CRP obviously decreased after treatment in the two groups, but serum levels of TNF-alpha and IL-6 obviously decreased only in the treatment group (P<0.05). The total effective rate was obviously higher in the treatment group than in the control group (70.00% vs. 43.33%, P<0.01).
  
  
  CONCLUSIONS
  CHR could efficiently improve the renal function of phase 3 CKD patients and alleviate the micro-inflammation.
authors.forename: Xue-zhong
authors.initials: XZ
authors.lastname: Gong
authors.forename: Ling-fang
authors.initials: LF
authors.lastname: Zhou
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.forename: Xiao-chun
authors.initials: XC
authors.lastname: Tang
authors.forename: Yu-run
authors.initials: YR
authors.lastname: Qian
authors.forename: Yue-rong
authors.initials: YR
authors.lastname: Wang
authors.forename: Lan
authors.initials: L
authors.lastname: Lu
authors.forename: Jia-jun
authors.initials: JJ
authors.lastname: Zhou
mesh_terms: D000328:Adult; D001806:Blood Urea Nitrogen; D002097:C-Reactive Protein / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007249:Inflammation; D015850:Interleukin-6 / Q000378:metabolism; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014508:Urea
chemical_list: D004365:Drugs, Chinese Herbal; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D014508:Urea; D002097:C-Reactive Protein; D019808:Losartan